Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Fungal ABC transporter-associated activity of isoflavonoids from the root extract of Dalea formosa.

Belofsky G, Kolaczkowski M, Adams E, Schreiber J, Eisenberg V, Coleman CM, Zou Y, Ferreira D.

J Nat Prod. 2013 May 24;76(5):915-25. doi: 10.1021/np4000763. Epub 2013 Apr 30.

PMID:
23631483
2.

ABC transporter Cdr1p contributes more than Cdr2p does to fluconazole efflux in fluconazole-resistant Candida albicans clinical isolates.

Holmes AR, Lin YH, Niimi K, Lamping E, Keniya M, Niimi M, Tanabe K, Monk BC, Cannon RD.

Antimicrob Agents Chemother. 2008 Nov;52(11):3851-62. doi: 10.1128/AAC.00463-08. Epub 2008 Aug 18.

3.

Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters.

Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod M, Bille J.

Antimicrob Agents Chemother. 1995 Nov;39(11):2378-86.

4.

A prenylated flavanone from Dalea elegans inhibits rhodamine 6 G efflux and reverses fluconazole-resistance in Candida albicans.

Peralta MA, Calise M, Fornari MC, Ortega MG, Diez RA, Cabrera JL, PĂ©rez C.

Planta Med. 2012 Jun;78(10):981-7. doi: 10.1055/s-0031-1298627. Epub 2012 Jun 6.

PMID:
22673834
5.

Reversal of antifungal resistance mediated by ABC efflux pumps from Candida albicans functionally expressed in yeast.

Schuetzer-Muehlbauer M, Willinger B, Egner R, Ecker G, Kuchler K.

Int J Antimicrob Agents. 2003 Sep;22(3):291-300.

PMID:
13678837
6.

Substrates and modulators of the multidrug transporter Cdr1p of Candida albicans in antifungal extracts of medicinal plants.

Kolaczkowski M, Kolaczkowska A, Sroda K, Ramalhete C, Michalak K, Mulhovo S, Ferreira MJ.

Mycoses. 2010 Jul;53(4):305-10. doi: 10.1111/j.1439-0507.2009.01711.x. Epub 2009 May 13.

PMID:
19460101
7.
8.

Antifungal activity of a prenylated flavonoid from Dalea elegans against Candida albicans biofilms.

Peralta MA, da Silva MA, Ortega MG, Cabrera JL, Paraje MG.

Phytomedicine. 2015 Oct 15;22(11):975-80. doi: 10.1016/j.phymed.2015.07.003. Epub 2015 Jul 26.

PMID:
26407939
9.

Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance.

Sanguinetti M, Posteraro B, Fiori B, Ranno S, Torelli R, Fadda G.

Antimicrob Agents Chemother. 2005 Feb;49(2):668-79.

10.

Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors.

Sanglard D, Ischer F, Monod M, Bille J.

Antimicrob Agents Chemother. 1996 Oct;40(10):2300-5.

11.

Regulated overexpression of CDR1 in Candida albicans confers multidrug resistance.

Niimi M, Niimi K, Takano Y, Holmes AR, Fischer FJ, Uehara Y, Cannon RD.

J Antimicrob Chemother. 2004 Dec;54(6):999-1006. Epub 2004 Oct 14.

PMID:
15486081
12.

Inhibitors of the Candida albicans Major Facilitator Superfamily Transporter Mdr1p Responsible for Fluconazole Resistance.

Keniya MV, Fleischer E, Klinger A, Cannon RD, Monk BC.

PLoS One. 2015 May 7;10(5):e0126350. doi: 10.1371/journal.pone.0126350. eCollection 2015.

13.

Divergent functions of three Candida albicans zinc-cluster transcription factors (CTA4, ASG1 and CTF1) complementing pleiotropic drug resistance in Saccharomyces cerevisiae.

Coste AT, Ramsdale M, Ischer F, Sanglard D.

Microbiology. 2008 May;154(Pt 5):1491-501. doi: 10.1099/mic.0.2007/016063-0.

PMID:
18451058
14.

Functional expression of Candida albicans drug efflux pump Cdr1p in a Saccharomyces cerevisiae strain deficient in membrane transporters.

Nakamura K, Niimi M, Niimi K, Holmes AR, Yates JE, Decottignies A, Monk BC, Goffeau A, Cannon RD.

Antimicrob Agents Chemother. 2001 Dec;45(12):3366-74.

15.

Overexpression of Candida albicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptibility.

Niimi K, Maki K, Ikeda F, Holmes AR, Lamping E, Niimi M, Monk BC, Cannon RD.

Antimicrob Agents Chemother. 2006 Apr;50(4):1148-55.

16.

Chemosensitization of fluconazole resistance in Saccharomyces cerevisiae and pathogenic fungi by a D-octapeptide derivative.

Niimi K, Harding DR, Parshot R, King A, Lun DJ, Decottignies A, Niimi M, Lin S, Cannon RD, Goffeau A, Monk BC.

Antimicrob Agents Chemother. 2004 Apr;48(4):1256-71.

17.

Chimeras of Candida albicans Cdr1p and Cdr2p reveal features of pleiotropic drug resistance transporter structure and function.

Tanabe K, Lamping E, Nagi M, Okawada A, Holmes AR, Miyazaki Y, Cannon RD, Monk BC, Niimi M.

Mol Microbiol. 2011 Oct;82(2):416-33. doi: 10.1111/j.1365-2958.2011.07820.x. Epub 2011 Sep 19.

18.

cDNA microarray analysis of differential gene expression and regulation in clinically drug-resistant isolates of Candida albicans from bone marrow transplanted patients.

Xu Z, Zhang LX, Zhang JD, Cao YB, Yu YY, Wang DJ, Ying K, Chen WS, Jiang YY.

Int J Med Microbiol. 2006 Oct;296(6):421-34. Epub 2006 Jun 19.

PMID:
16782404
19.
20.

Effects of cetylpyridinium chloride resistance and treatment on fluconazole activity versus Candida albicans.

Edlind MP, Smith WL, Edlind TD.

Antimicrob Agents Chemother. 2005 Feb;49(2):843-5.

Supplemental Content

Support Center